BUSINESS AREA
Labtech
Companies in the Labtech business area are active in the market areas diagnostics, biomedical research and laboratory equipment.
| Q2 | Q2 | ∆ | Jan-Jun | Jan-Jun | ∆ | Jul 2024- | Full year | |
| SEKm | 2025 | 2024 | % | 2025 | 2024 | % | Jun 2025 | 2024 |
| Net sales | 985 | 941 | 5 | 1,974 | 1,804 | 9 | 3,967 | 3,797 |
| Organic growth, % | 6 | 8 | 9 | 2 | – | 3 | ||
| EBITA | 122 | 109 | 12 | 242 | 208 | 16 | 479 | 445 |
| EBITA margin, % | 12.4 | 11.6 | 12.2 | 11.5 | 12.1 | 11.7 |
Labtech's net sales increased by 5 percent in the second quarter to SEK 985m (941). Growth, excluding currency effects, amounted to 9 percent, of which organic growth was 6 percent and acquired growth was 3 percent. Exchange rate changes had a negative impact on net sales by 4 percent. EBITA increased by 12 percent to SEK 122m (109), corresponding to an EBITA margin of 12.4 percent (11.6). Exchange rate fluctuations had a negative impact on EBITA, corresponding to SEK -4m.
Labtech’s net sales in the interim period increased by 9 percent to SEK 1,974m (1,804), of which organic sales increased by 9 percent and acquired growth amounted to 3 percent. Exchange rate changes had a negative impact on net sales by 3 percent. EBITA increased by 16 percent to SEK 242m (208), corresponding to an EBITA margin of 12.2 percent (11.5).
Labtech had a strong second quarter, with high growth and improved margins. Demand from customers in diagnostics is stable and growing. Growth and margin improvements were driven by tenders won from competitors as well as tenders where trust was renewed, but at higher prices. The companies’ activities in areas such as veterinary medicine, Alzheimer’s diagnostics, point of care, advanced molecular diagnostics, and digital pathology also contributed positively to the development.
In academic research, there is still some hesitation, and sales cycles for larger capital investments remain long, while sales of consumables and reagents continue to drive growth. Sales to customers in the industrial sector are steadily increasing.
During the quarter, training and experience sharing between the companies took place, focusing on gene sequencing (NGS). This is an area characterized by rapid development and strong growth. Several companies are carrying out targeted efforts to streamline internal processes, which are expected to strengthen profitability over time.
|
Dynamisk graf: Net sales (SEKm)
|
Dynamisk graf: Net sales per market 2025
|
|
Dynamisk graf: EBITA (SEKm)
|
Dynamisk graf: EBITA margin (%)
|